Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

International Journal of Cancer

Volumn 100, Issue 6, 2002, Pages 690-697

  Dreier, Torsten ^a,b   Lorenczewski, Grit ^a   Brandl, Christian ^a   Hoffmann, Patrick ^b   Syring, Uwe ^a,d   Hanakam, Frank ^c   Kufer, Peter ^a   Riethmuller, Gert ^d   Bargou, Ralf ^c   Baeuerle, Patrick A ^a,b,c,d  

^a MICROMET AG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d NONE   (Germany)

Author keywords

B cell lymphoma; Bispecific antibody; CD19; T cell activation

Indexed keywords

BISPECIFIC ANTIBODY; CD45 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY CD3; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; CATALYSIS; CELL IMMORTALIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOMA CELL; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD3; CELL SEPARATION; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; KINETICS; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037143806     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10557     Document Type: Article

References (41)

1. Clinical trials of antibody therapy
2. Improving the efficacy of antibody-based cancer therapies
3. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity
4. Bispecific antibodies in cancer therapy
5. Bi-specific antibody therapy for the treatment of cancer
6. The immunological synapse
7. Organization of plasma membrane functional rafts upon T cell activation
8. Rituximab as first-line systemic treatment for patients with low-grade lymphoma
9. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
10. Prostate-specific membrane antigen: Current and future utility
11. Bispecific human IgG by design
12. Current perspectives of bispecific antibody-based immunotherapy
13. Bispecific and bifunctional single chain recombinant antibodies
14. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity
15. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas
16. Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: A new strategy in the treatment of chronic inflammatory diseases and HIV
17. Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein
18. + natural-killer-like T lymphocytes to EpCAM-expressing tumor cells
19. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model
20. Biological properties of a bispecific single-chain antibody directed against 17-IA (EpCAM) and CD3: Tumor cell-dependent T cell stimulation and cytotoxic activity
21. Mono- and bispecific single-chain antibody fragments for cancer therapy
22. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria
23. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli
24. A recombinant bispecific single-chain antibody, CD19xCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
25. Antibody-targeted therapy for low-grade lymphoma
26. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy
27. The efficacy of CD3xCD19 bispecific monoclonal antibody BsAb in clonogenic assay: The effect of repeated addition of BsAb and interleukin-2
28. Immunotherapeutic strategies for the treatment of plasma cell malignancies
29. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity
30. Determination of affinities of murine and chimeric anti α/β T-cell receptor antibodies by flow cytometry
31. Bispecific CD3xCD19 diabody for T cell-mediated lysis of malignant human B cells
32. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3xCd19 tandem diabody and CD28 costimulation
33. Treatment of human B cell lymphoma xenografts with a CD3xCD19 diabody and T cells
34. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3xCD19 bispecific antibodies in combination with bivalent CD28 antibodies
35. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancies
36. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody
37. The role of T-cell receptor dimerization in T-cell activation
38. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
39. A new microcellular cytotoxicity test based on calcein AM release
40. Herpesvirus saimiri transformed human T cell lines: A permissive system for human immunodeficiency viruses